The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of the EZH1/2 inhibitor valemetostat tosylate (DS-3201b) in pediatric patients with malignant solid tumors (NCCH1904): A multicenter phase I trial.
 
Ayumu Arakawa
Honoraria - Abbvie; Chugai Pharma; Lilly; Ohara Pharmaceutical; Ono Pharmaceutical
Research Funding - Chugai Pharma (Inst); Takeda (Inst)
 
Kanako Kondo
No Relationships to Disclose
 
Akihiro Hirakawa
Consulting or Advisory Role - Abbvie; Astellas Pharma; Chugai Pharma; Fuji Pharma; Kissei Pharmaceutical; Kyowa Kirin International; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - Mitsubishi Tanabe Pharma; Pfizer; Takeda
 
Ryo Sadachi
No Relationships to Disclose
 
Yoshie Shuda
No Relationships to Disclose
 
Kazumi Kurishita
No Relationships to Disclose
 
Reiko Ando
No Relationships to Disclose
 
Yoshimasa Saito
No Relationships to Disclose
 
Keita Terashima
Honoraria - Alexion Pharmaceuticals; AstraZeneca; Bayer; Konica Minolta Realm; Novartis
Consulting or Advisory Role - Alexion Pharmaceuticals
Research Funding - AstraZeneca (Inst); Lilly; Novartis (Inst); Ohara Pharmaceutical (Inst)
 
Bunpei Miyazaki
No Relationships to Disclose
 
Kenichi Nakamura
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim Seiyaku (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); SERVIER (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Chitose Ogawa
Honoraria - Chugai Pharma
Consulting or Advisory Role - Kyowa Kirin Co., Ltd.; Ono Pharmaceutical; Pfizer
Speakers' Bureau - Ohara Pharmaceutical
Research Funding - Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst)